Phesgo 600mg, 1200mg (SC) Pertuzumab Trastuzumab
Intended for healthcare professionals only
This material should not be used as a substitute for professional medical advice or to promote any medication. For more information, please consult your physician
Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase) injection, for subcutaneous use, is a HER2/neu receptor antagonist.
It is indicated for use in combination with chemotherapy as neoadjuvant treatment (this is the treatment given as a first step) of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen for early breast cancer, adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence, and in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
If a patient becomes pregnant while receiving Phesgo or within 7 months following the last dose of Phesgo, please immediately report pregnancy to the local Roche Adverse Event Line at +92 301 8287010 or email at [email protected]
Full prescribing information is available on request.
If you have a scientific query related to one of Roche's products, please contact us at [email protected]
In case of any adverse events or safety queries, please contact [email protected]
M-PK-00002297
Solutions
Pharma Products
![[Product] Phesgo](https://assets.roche.com/f/169232/1600x1065/eaf3995b9f/phesgo-600.png/m/320x180/filters:format(webp):quality(90)/)